Hybridoma technology is a method for producing large quantities of monoclonal antibodies by fusing specific antibody-producing B cells with myeloma cells, creating hybrid cells that can both proliferate indefinitely and produce a single type of antibody. This technology revolutionized immunology and has vast applications in diagnostics, therapeutics, and research.